Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results
November 10, 2021 05:55 ET
|
Novan, Inc.
– Company executing on plans for three potential New Drug Application (NDA) filings in three years with the first submission targeted in Q3 2022 for lead program SB206 in molluscum contagiosum – –...
Novan Completes End-of-Phase 2 Meeting and Provides Additional Business Updates
March 11, 2019 08:00 ET
|
Novan, Inc.
Completed end-of-Phase 2 FDA meeting for molluscum contagiosumMeeting minutes received and support second quarter 2019 pivotal Phase 3 initiationFinalizing establishment of Irish entity to enable EU...
Novan Extends Technical Production Capacity and Reaches Agreement with Orion Corporation
October 16, 2018 08:05 ET
|
Novan, Inc.
External manufacturing agreement reached to enable production of clinical trial materials for SB204 and the acne indication, with the potential to include additional product candidatesExtension of...
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
October 08, 2018 08:00 ET
|
Novan, Inc.
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
Novan Receives FDA Guidance for SB204 and Acne Indication
September 24, 2018 16:15 ET
|
Novan, Inc.
Written minutes received from Type C meeting with FDAModerate-to-severe patient pathway re-affirmedAdditional insights gained around the severe patient sub-population MORRISVILLE, N.C., Sept. 24,...
Novan to Present Integrated Data from Phase 3 Trials with SB204 for Treatment of Acne
February 13, 2018 08:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that data from the Company’s two Phase 3 clinical trials and long-term...
Novan Announces Plan to Complete Development of SB204 Acne Candidate via Third Party Funding and Execution
November 07, 2017 08:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that it has agreed in principle to a business structure that would enable...
Novan Conducts Guidance Meeting with FDA on SB204 Development Program
September 25, 2017 08:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that it has concluded a guidance meeting with the U.S. Food and Drug...
Novan to Present Safety and Efficacy Data for SB204 Program in Adolescents at 13th World Congress of Pediatric Dermatology
July 07, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., July 07, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that pharmacokinetic, safety and efficacy data for SB204, an investigational...
Novan Presents Safety Data for SB204 Program
April 27, 2017 09:13 ET
|
Novan, Inc.
MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that pharmacokinetic data for SB204, a once-daily, topical monotherapy for...